Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Peterschmitt, M. J., Saiki, H., Hatano, T., Gasser, T., Isaacson, S. H., Gaemers, S. J. M., Minini, P., Saubadu, S., Sharma, J., Walbillic, S., Alcalay, R. N., Cutter, G., Hattori, N., Höglinger, G. U., Marek, K., Schapira, A. H. V., Scherzer, C. R., Simuni, T., … Fischer, T. Z. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson’s Disease, 12(2), 557–570. https://doi.org/10.3233/jpd-212714
Authors:
M. Judith Peterschmitt
Sergio Pablo Sardi
Tanya Z. Fischer
Hidemoto Saiki
Taku Hatano
Nobutaka Hattori
Thomas Gasser
Stuart H. Isaacson
Sebastiaan J. M. Gaemers
Pascal Minini
Stephane Saubadu
Samantha Walbillic
Jyoti Sharma
Roy N. Alcalay
Gary Cutter
Gunter U. Hoeglinger
Kenneth Marek
Anthony H. Schapira
Clemens R. Scherzer
Tanya Simuni
Nir Giladi
Affiliated Authors:
Roy N. Alcalay
Author Keywords:
parkinson's disease
moves-pd
venglustat (gz/sar402671)
glucocerebrosidase gene (gba)
glucosylceramide (gl-1)
glucosylceramide synthase (gcs) inhibition
gba-pd
Publication Type:
Article
Unique ID:
10.3233/JPD-212714
PMID:
Publication Date:
Data Source:
Web of Science

Record Created: